Med. praxi 2012; 9(8-9): 319-324

Combination treatment for hypertension in the year 2012

prof.MUDr.Jindřich ©pinar, CSc., FESC1, prof.MUDr.Jiří Vítovec, CSc.2
1 Interní kardiologická klinika FN Brno a LF MU, Brno
2 I. interní kardioangiologická klinika FN u sv. Anny a LF MU, Brno

In the year 2007, new European guidelines on the diagnosis and treatment of hypertension were issued, followed by both Czech and

British guidelines in 2008 and by the Reappraisal of European Guidelines in 2009. In 2011, new NICE (British) guidelines were released

and new Czech Society of Hypertension guidelines are prepared in 2012. The individual guidelines are very similar, still some differences

exist. The Czech Society of Hypertension has adopted the European classification with three prehypertension grades (optimal, normal,

and high-normal blood pressure), three grades of hypertension, and isolated systolic hypertension as an independent entity. The management

of hypertension mainly consists in achievement of normotension and use of combination treatment according to comorbid

conditions. Good control of systolic blood pressure as well as control for additional risk parameters is essential.

The most commonly recommended double combinations include a renin-angiotensin-aldosterone system (RAAS) blocker – an ACEI or

a sartan plus a calcium blocker, followed by a renin-angiotensin-aldosterone system blocker plus a diuretic, and a calcium blocker plus

a diuretic. Recently, a fixed combination of a calcium blocker plus a beta blocker has emerged. Recommended diuretics include primarily

indapamide, secondly chlorthalidone; by contrast, hydrochlorothiazide is viewed critically.

The main advantage of fixed combinations is increased patient compliance and, thus, better control of hypertension. We present

an overview of fixed combinations of RAAS blockers plus calcium blockers registered in the Czech Republic as of May 2012.

Keywords: hypertension, guidelines, combination treatment, fixed combination

Published: September 25, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J. Combination treatment for hypertension in the year 2012. Med. praxi. 2012;9(8-9):319-324.
Download citation

References

  1. Widimský J jr., Cífková R, ©pinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008; 50: K3-K16.
  2. Widimský J, a kol. Hypertenze 2. vydání. Triton Praha 2004: 590.
  3. Zanchetti A for the guidelines committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011-1023. Go to original source... Go to PubMed...
  4. Mancia G, Laurent S, Agabiti-Rosei L, et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force dokument. Journal of Hypertension 2009; 27(11): 2121-2158. Go to original source... Go to PubMed...
  5. ©pinar J, Vítovec J, Zicha J. Hypertenze - diagnostika a léčba. Grada 1999: 228.
  6. ©pinar J, Vítovec J. Vývoj doporučení pro léčbu hypertenze. Vnitřní lékařství 2005; 51(3): 75-82.
  7. Cífková R, ©kodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28: 2196-2203. Go to original source... Go to PubMed...
  8. Cobanian AV, Bakris BL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572. Go to original source... Go to PubMed...
  9. Williams B, Poulter NR, Brown JM, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ 2004; 328: 634-640. Go to original source... Go to PubMed...
  10. Vítovec J, ©pinar J. Farmakoterapie kardiovaskulárních onemocnění. Grada 2004: 248.
  11. ©pinar J, Vítovec J. Kombinační léčba hypertenze. Causa Subita 2012; 15(1): 10-13.
  12. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120(8): 713-719. Go to original source... Go to PubMed...
  13. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300. Go to original source... Go to PubMed...
  14. Blood presure lowering trialist colaboration: Effect of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 238: 1121-1128.
  15. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr 2010; 2: 44. Go to original source... Go to PubMed...
  16. Souček M, Řiháček I. Léčba hypertenze v rámci metabolického syndromu. Kardiologická revue 2010; 12(2): 73-76.
  17. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
  18. Poulter NR fot the ASCOT investigators: Role of blood pressure and other variables in the differential cardiovascular event rate noted in the the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
  19. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181. Go to original source... Go to PubMed...
  20. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
  21. Pepine CJ. for the INVEST investigators: INVEST: International Verapamil SR/Trandolapril Study. JAMA 2003; 290: 2805-2816. Go to original source... Go to PubMed...
  22. Zou Z, Xu FY, Wang L, et al. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials. J Hum Hypertens 2011; 25: 203-210. Go to original source... Go to PubMed...
  23. Dahlof B, Devereux RB, Kjeldsen SE for the LIFE investigators: Cardovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
  24. Makita S, Abiko A, Naganuma Y, et al. Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. Clin Exp Hypertens 2009; 31: 105-115. Go to original source... Go to PubMed...
  25. Patel A. ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
  26. Vítovec J, ©pinar J. Perindopril/indapamid - fixní kombinace. Remedia 2007; 17: 247-257.
  27. Řiháček I, Řiháčková E. Kardioprotektivní kombinace v léčbě hypertenze - betablokátory a blokátory kalciových kanálů typu dihydropyridinů. Cazsa Subita 2012; 15(1): 46-48.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.